Acquired aneurysmal subarachnoid hemorrhage
disease diseaseOn this page
Summary
Acquired aneurysmal subarachnoid hemorrhage (MONDO:0019543) is a disease. A subtype of subarachnoid hemorrhage — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 34
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | 10 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
34 HPO clinical features (Orphanet curated; top 34 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0009145 | Abnormal cerebral artery morphology | Very frequent (80-99%) |
| HP:0000822 | Hypertension | Frequent (30-79%) |
| HP:0001133 | Constriction of peripheral visual field | Frequent (30-79%) |
| HP:0001259 | Coma | Frequent (30-79%) |
| HP:0001342 | Cerebral hemorrhage | Frequent (30-79%) |
| HP:0002013 | Vomiting | Frequent (30-79%) |
| HP:0002018 | Nausea | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0002354 | Memory impairment | Frequent (30-79%) |
| HP:0012250 | ST segment depression | Frequent (30-79%) |
| HP:0025637 | Vasospasm | Frequent (30-79%) |
| HP:0100543 | Cognitive impairment | Frequent (30-79%) |
| HP:0000238 | Hydrocephalus | Occasional (5-29%) |
| HP:0000505 | Visual impairment | Occasional (5-29%) |
| HP:0000821 | Hypothyroidism | Occasional (5-29%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0001279 | Syncope | Occasional (5-29%) |
| HP:0001635 | Congestive heart failure | Occasional (5-29%) |
| HP:0001658 | Myocardial infarction | Occasional (5-29%) |
| HP:0001712 | Left ventricular hypertrophy | Occasional (5-29%) |
| HP:0001974 | Leukocytosis | Occasional (5-29%) |
| HP:0002140 | Ischemic stroke | Occasional (5-29%) |
| HP:0002344 | Progressive neurologic deterioration | Occasional (5-29%) |
| HP:0002490 | Increased CSF lactate | Occasional (5-29%) |
| HP:0002637 | Cerebral ischemia | Occasional (5-29%) |
| HP:0003074 | Hyperglycemia | Occasional (5-29%) |
| HP:0003124 | Hypercholesterolemia | Occasional (5-29%) |
| HP:0004302 | Functional motor deficit | Occasional (5-29%) |
| HP:0005184 | Prolonged QTc interval | Occasional (5-29%) |
| HP:0006824 | Cranial nerve paralysis | Occasional (5-29%) |
| HP:0030955 | Alcoholism | Occasional (5-29%) |
| HP:0031058 | Impairment of activities of daily living | Occasional (5-29%) |
| HP:0031885 | Hyperglycorrhachia | Occasional (5-29%) |
| HP:0040075 | Hypopituitarism | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | acquired aneurysmal subarachnoid hemorrhage |
| Mondo ID | MONDO:0019543 |
| Orphanet | 90065 |
| ICD-11 | 958976948 |
| UMLS | C0338572 |
| MedGen | 572642 |
| GARD | 0019114 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of subarachnoid hemorrhage. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebrovascular disorder › stroke disorder › hemorrhagic stroke › subarachnoid hemorrhage › acquired aneurysmal subarachnoid hemorrhage
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.